S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
NASDAQ:ESPR

Esperion Therapeutics News Headlines

$5.25
-3.72 (-41.47%)
(As of 12/3/2021 04:00 PM ET)
Add
Compare
Today's Range
$4.96
$6.10
50-Day Range
$5.25
$12.62
52-Week Range
$4.96
$39.49
Volume
28.74 million shs
Average Volume
1.70 million shs
Market Capitalization
$152.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.91

Media Mentions By Week



Esperion Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ESPR
News Sentiment

0.54

0.31

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ESPR Articles
This Week

6

1

ESPR Articles
Average Week

Get Esperion Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter.

Esperion Therapeutics (NASDAQ:ESPR) News Headlines Today

SourceHeadline
MarketBeat logoStock Traders Purchase Large Volume of Call Options on Esperion Therapeutics (NASDAQ:ESPR)
americanbankingnews.com - December 3 at 1:20 PM
finance.yahoo.com logoEsperion Announces Pricing of $225 Million Public Offering
finance.yahoo.com - December 3 at 4:07 AM
finance.yahoo.com logoWhy Is Esperion Therapeutics (ESPR) Down 24.5% Since Last Earnings Report?
finance.yahoo.com - December 2 at 5:19 PM
finance.yahoo.com logoEsperion Announces Proposed Public Offering
finance.yahoo.com - December 2 at 5:19 PM
MarketBeat logoEsperion Therapeutics, Inc. (NASDAQ:ESPR) Given Consensus Rating of "Hold" by Brokerages
americanbankingnews.com - November 27 at 9:44 AM
MarketBeat logo Analysts Expect Esperion Therapeutics, Inc. (NASDAQ:ESPR) Will Announce Quarterly Sales of $15.09 Million
americanbankingnews.com - November 27 at 5:54 AM
MarketBeat logoEsperion Therapeutics, Inc. (NASDAQ:ESPR) Expected to Post Earnings of -$2.74 Per Share
americanbankingnews.com - November 25 at 5:14 AM
markets.businessinsider.com logoPre-market Movers: OCUP, KTTA, GAME, BIOL, JWN…
markets.businessinsider.com - November 24 at 8:02 AM
finance.yahoo.com logoImplied Volatility Surging for Esperion Therapeutics (ESPR) Stock Options
finance.yahoo.com - November 19 at 7:56 PM
finance.yahoo.com logoEsperion Presents Important New Science Highlighting Potential Benefits of NEXLETOL® (bempedoic acid) Tablets at American Heart Association Scientific Sessions 2021
finance.yahoo.com - November 12 at 7:27 AM
finance.yahoo.com logoEsperion Therapeutics, Inc. (NASDAQ:ESPR): Are Analysts Optimistic?
finance.yahoo.com - November 6 at 10:30 AM
finance.yahoo.com logoEsperion (ESPR) Beats on Q3 Earnings, Lowers Expense Guidance
finance.yahoo.com - November 2 at 3:34 PM
ca.finance.yahoo.com logoEsperion Reports Third Quarter 2021 Financial Results and Provides Company Update
ca.finance.yahoo.com - November 2 at 10:34 AM
finance.yahoo.com logoEsperion to Present Key Science at the American Heart Association Scientific Sessions 2021
finance.yahoo.com - November 1 at 6:07 PM
finance.yahoo.com logoEsperion Announces the Appointment of Seth H.Z. Fischer to its Board of Directors
finance.yahoo.com - November 1 at 8:02 AM
finance.yahoo.com logoEsperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
finance.yahoo.com - October 26 at 10:14 PM
finance.yahoo.com logoWhy Esperion Therapeutics Plummeted by 11% Today
finance.yahoo.com - October 25 at 9:11 PM
finance.yahoo.com logoESPERION Announces Agreement to Exchange $15 Million in Principal Amount of its 4.00% Convertible Senior Subordinated Notes due 2025 for Common Stock
finance.yahoo.com - October 25 at 11:10 AM
finance.yahoo.com logoEsperion (ESPR) to Cut 40% Workforce, Revamp Cost Structure
finance.yahoo.com - October 19 at 12:28 PM
finance.yahoo.com logoEsperion Plans Expense & Operational Structure Alignment; Shares Fall 1.5% Pre-Market
finance.yahoo.com - October 18 at 1:55 PM
finance.yahoo.com logoESPERION Announces Plan for Transformative Long-Term Growth
finance.yahoo.com - October 18 at 8:54 AM
finance.yahoo.com logoEsperion Therapeutics to reduce workforce by 40%
finance.yahoo.com - October 18 at 8:54 AM
finance.yahoo.com logoEsperion to Report Third Quarter 2021 Financial Results November 2, 2021
finance.yahoo.com - October 12 at 10:18 AM
finance.yahoo.com logoEsperion Therapeutics Provides ETC-1002 Development Program Update; Reports Fourth Quarter and Full Year 2014 Financial Results
finance.yahoo.com - September 12 at 11:27 PM
finance.yahoo.com logo3 “Strong Buy” Stocks Flirting With a Bottom
finance.yahoo.com - September 9 at 11:32 AM
finance.yahoo.com logoESPERION to Host Investor Webinar on the Current Landscape and Future Directions in the Treatment of Elevated Cholesterol
finance.yahoo.com - September 7 at 7:27 PM
finance.yahoo.com logoEsperion Therapeutics (ESPR) Down 5.9% Since Last Earnings Report: Can It Rebound?
finance.yahoo.com - September 2 at 6:19 PM
finance.yahoo.com logoIf You Had Bought Esperion Therapeutics' (NASDAQ:ESPR) Shares Three Years Ago You Would Be Down 69%
finance.yahoo.com - August 8 at 1:00 PM
finance.yahoo.com logoEsperion (ESPR) Q2 Loss Narrower Than Expected, Drug Price Up
finance.yahoo.com - August 4 at 1:56 PM
finance.yahoo.com logoEsperion Therapeutics, inc (ESPR) Q2 2021 Earnings Call Transcript
finance.yahoo.com - August 4 at 12:16 AM
finance.yahoo.com logoEsperion Therapeutics (ESPR) Reports Q2 Loss, Misses Revenue Estimates
finance.yahoo.com - August 3 at 2:15 PM
finance.yahoo.com logoESPERION Reports Second Quarter 2021 Financial Results and Provides Company Update
finance.yahoo.com - August 3 at 8:09 AM
finance.yahoo.com logoEarnings Preview: Esperion Therapeutics (ESPR) Q2 Earnings Expected to Decline
finance.yahoo.com - July 27 at 7:24 PM
finance.yahoo.com logoEsperion to Participate in Upcoming Virtual Investor Conference
finance.yahoo.com - July 27 at 9:23 AM
nasdaq.com logoEsperion Therapeutics, Inc. Common Stock (ESPR)
nasdaq.com - July 16 at 11:56 PM
nasdaq.com logoThe Esperion Therapeutics (NASDAQ:ESPR) Share Price Is Up 68% And Shareholders Are Holding On
nasdaq.com - July 14 at 11:28 AM
finance.yahoo.com logoEsperion to Report Second Quarter 2021 Financial Results August 3, 2021
finance.yahoo.com - July 13 at 9:20 AM
finance.yahoo.com logoESPERION Appoints JoAnne Micale Foody, MD, FACC, FAHA as Chief Medical Officer
finance.yahoo.com - June 28 at 12:45 PM
uk.finance.yahoo.com logoESPR Jul 2021 12.500 put
uk.finance.yahoo.com - June 23 at 2:45 PM
uk.finance.yahoo.com logoESPR Jul 2021 30.000 put
uk.finance.yahoo.com - June 23 at 9:22 AM
finance.yahoo.com logoWhy Is Esperion Therapeutics (ESPR) Up 6.4% Since Last Earnings Report?
finance.yahoo.com - June 3 at 2:44 PM
finance.yahoo.com logoSimulation Model based on Pooled Phase 3 Data Demonstrating NEXLETOL® (bempedoic acid) Tablet’s Potential to Lower Absolute Cardiovascular Event Risk Presented at ACC.21
finance.yahoo.com - May 15 at 1:43 PM
finance.yahoo.com logoDaily – Vickers Top Buyers & Sellers for 05/10/2021
finance.yahoo.com - May 11 at 9:45 AM
finance.yahoo.com logoAnalysts Just Slashed Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) EPS Numbers
finance.yahoo.com - May 9 at 9:35 AM
seekingalpha.com logoEsperion Therapeutics, Inc. (ESPR) CEO Timothy Mayleben on Q1 2021 Results - Earnings Call Transcript
seekingalpha.com - May 6 at 1:45 PM
finance.yahoo.com logoWhy Esperion Therapeutics Plummeted Nearly 22% Today
finance.yahoo.com - May 5 at 10:44 PM
markets.businessinsider.com logoMid-Day Market Update: Crude Oil Rises 1%; Esperion Therapeutics Shares Drop Following Q1 Results
markets.businessinsider.com - May 5 at 5:43 PM
msn.com logoEsperion Stock Plummets On Wider Than Expected Q1 Earnings Loss; Analysts Move To Sidelines
msn.com - May 5 at 5:43 PM
markets.businessinsider.com logoWhere Esperion Therapeutics Stands With Analysts
markets.businessinsider.com - May 5 at 12:27 PM
finance.yahoo.com logoEsperion (ESPR) Q1 Earnings Miss, Lower Drug Price Hits Sales
finance.yahoo.com - May 5 at 12:27 PM
Get Esperion Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 12/4/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.